Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Fertil Steril ; 107(6): 1341-1347.e1, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28501362

RESUMO

OBJECTIVE: To study whether infertility treatments, including IVF and non-IVF fertility treatments, are associated with diseases of placental insufficiency in early gestation. First trimester placental volumes by ultrasound and chorionic villi weight during sampling (CVS) were performed to detect differences between pregnancies conceived spontaneously versus with fertility treatments. DESIGN: Retrospective cohort. SETTING: Academic tertiary center. PATIENT(S): Women with singleton pregnancies undergoing CVS and first trimester ultrasound from April 2007 to November 2015. INTERVENTION(S): Estimated placental volume (EPV) was calculated from ultrasound images using a validated computation and CVS estimated tissue weight was performed using a validated visual analogue scale. MAIN OUTCOME MEASURE(S): Adjusted linear regression was used to compare EPV and CVS weight based on mode of conception. RESULT(S): A total of 1,977 spontaneous and 334 conceived with fertility treatments (133 non-IVF and 201 IVF) pregnancies were included. Significant differences in maternal age, gravidity, hypertension, and smoking status were identified. EPV and CVS weight were correlated with maternal age, gestational age, and maternal hypertension. Adjusted linear regression showed no difference in EPV in pregnancies conceived with fertility treatments versus spontaneously. The CVS weight was significantly lower in the IVF conceptions in unadjusted univariate analyses. However, after adjusted regression, this was no longer significant. CONCLUSION(S): Mode of conception does not appear to affect first trimester placental size. As differences in maternal age, hypertension, and smoking status differ among the groups and are correlated to placental size, it may be the underlying patient population leading to abnormal placentation and insufficiency, not the fertility treatments used.


Assuntos
Infertilidade Feminina/fisiopatologia , Infertilidade Feminina/terapia , Placenta/fisiologia , Placentação/fisiologia , Primeiro Trimestre da Gravidez/fisiologia , Técnicas de Reprodução Assistida/estatística & dados numéricos , Adulto , California/epidemiologia , Estudos de Coortes , Feminino , Fertilização in vitro/estatística & dados numéricos , Humanos , Infertilidade Feminina/epidemiologia , Tamanho do Órgão/fisiologia , Gravidez , Prevalência , Reprodutibilidade dos Testes , Estudos Retrospectivos , Sensibilidade e Especificidade , Resultado do Tratamento
2.
Hum Reprod ; 31(4): 905-14, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26911863

RESUMO

STUDY QUESTION: Can whole exome sequencing (WES) and in vitro validation studies be used to find the causative genetic etiology in a patient with primary ovarian failure and infertility? SUMMARY ANSWER: A novel follicle-stimulating hormone receptor (FSHR) mutation was found by WES and shown, via in vitro flow cytometry studies, to affect membrane trafficking. WHAT IS KNOWN ALREADY: WES may diagnose up to 25-35% of patients with suspected disorders of sex development (DSD). FSHR mutations are an extremely rare cause of 46, XX gonadal dysgenesis with primary amenorrhea due to hypergonadotropic ovarian failure. STUDY DESIGN, SIZE, DURATION: A WES study was followed by flow cytometry studies of mutant protein function. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study subjects were two Turkish sisters with hypergonadotropic primary amenorrhea, their parents and two unaffected sisters. The affected siblings and both parents were sequenced (trio-WES). Transient transfection of HEK 293T cells was performed with a vector containing wild-type FSHR as well as the novel FSHR variant that was discovered by WES. Cellular localization of FSHR protein as well as FSH-stimulated cyclic AMP (cAMP) production was evaluated using flow cytometry. MAIN RESULTS AND THE ROLE OF CHANCE: Both affected sisters were homozygous for a previously unreported missense mutation (c.1222G>T, p.Asp408Tyr) in the second transmembrane domain of FSHR. Modeling predicted disrupted secondary structure. Flow cytometry demonstrated an average of 48% reduction in cell-surface signal detection (P < 0.01). The mean fluorescent signal for cAMP (second messenger of FSHR), stimulated by FSH, was reduced by 50% in the mutant-transfected cells (P < 0.01). LIMITATIONS, REASONS FOR CAUTION: This is an in vitro validation. All novel purported genetic variants can be clinically reported only as 'variants of uncertain significance' until more patients with a similar phenotype are discovered with the same variant. WIDER IMPLICATIONS OF THE FINDINGS: We report the first WES-discovered FSHR mutation, validated by quantitative flow cytometry. WES is a valuable tool for diagnosis of rare genetic diseases, and flow cytometry allows for quantitative characterization of purported variants. WES-assisted diagnosis allows for treatments aimed at the underlying molecular etiology of disease. Future studies should focus on pharmacological and assisted reproductive treatments aimed at the disrupted FSHR, so that patients with FSH resistance can be treated by personalized medicine. STUDY FUNDING/COMPETING INTERESTS: E.V. is partially funded by the DSD Translational Research Network (NICHD 1R01HD068138). M.S.B. is funded by the Neuroendocrinology, Sex Differences and Reproduction training grant (NICHD 5T32HD007228). The authors have no competing interests to disclose.


Assuntos
Modelos Moleculares , Mutação de Sentido Incorreto , Insuficiência Ovariana Primária/genética , Receptores do FSH/genética , Adulto , Consanguinidade , Exoma , Feminino , Estudo de Associação Genômica Ampla , Células HEK293 , Homozigoto , Humanos , Insuficiência Ovariana Primária/metabolismo , Estrutura Secundária de Proteína , Transporte Proteico , Receptores do FSH/química , Receptores do FSH/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Análise de Sequência de DNA , Irmãos , Turquia , Adulto Jovem
3.
Fertil Steril ; 103(1): 249-57, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25439840

RESUMO

OBJECTIVE: To determine whether follicular fluid (FF) cortisol levels affect cumulus cell (CC) lipid content during oocyte meiotic resumption, and whether CCs express genes for glucocorticoid action. DESIGN: Prospective cohort study. SETTING: Academic medical center. PATIENT(S): Thirty-seven nonobese women underwent ovarian stimulation for in vitro fertilization (IVF). INTERVENTION(S): At oocyte retrieval, FF was aspirated from the first follicle (>16 mm in size) of each ovary and pooled CCs were collected. MAIN OUTCOME MEASURE(S): Follicular fluid cortisol and cortisone analysis was performed with the use of liquid chromatography-tandem mass spectrometry. CCs were stained with lipid fluorescent dye Bodipy FL C16 to determine lipid content with the use of confocal microscopy. Quantitative real-time polymerase chain reaction was used to detect CC gene expression of 11ß-hydroxysteroid dehydrogenase (11ß-HSD) types 1 and 2, glucocorticoid receptor (NR3C1), lipoprotein lipase (LPL), and hormone-sensitive lipase (HSL). RESULT(S): Adjusting for maternal age, FF cortisol levels negatively correlated with CC lipid content and positively correlated with numbers of total and mature oocytes. CCs expressed genes for 11ß-HSD type 1 as the predominant 11ß-HSD isoform, NR3C1, LPL, and HSL. CONCLUSION(S): FF cortisol levels may regulate CC lipolysis during oocyte meiotic resumption and affect oocyte quality during IVF.


Assuntos
Células do Cúmulo/metabolismo , Hidrocortisona/metabolismo , Metabolismo dos Lipídeos , Meiose , Oócitos/metabolismo , Folículo Ovariano/metabolismo , Indução da Ovulação , Adulto , Células do Cúmulo/patologia , Metabolismo Energético , Feminino , Humanos , Pessoa de Meia-Idade , Oócitos/patologia , Estatística como Assunto
4.
Semin Reprod Med ; 31(5): 317-24, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23934691

RESUMO

Racial and ethnic health disparities in reproductive medicine exist across the life span and are costly and burdensome to our healthcare system. Reduction and ultimate elimination of health disparities is a priority of the National Institutes of Health who requires reporting of race and ethnicity for all clinical research it supports. Given the increasing rates of admixture in our population, the definition and subsequent genetic significance of self-reported race and ethnicity used in health disparity research is not straightforward. Some groups have advocated using self-reported ancestry or carefully selected single-nucleotide polymorphisms, also known as ancestry informative markers, to sort individuals into populations. Despite the limitations in our current definitions of race and ethnicity in research, there are several clear examples of health inequalities in reproductive medicine extending from puberty and infertility to obstetric outcomes. We acknowledge that socioeconomic status, education, insurance status, and overall access to care likely contribute to the differences, but these factors do not fully explain the disparities. Epigenetics may provide the biologic link between these environmental factors and the transgenerational disparities that are observed. We propose an integrated view of health disparities across the life span and generations focusing on the metabolic aspects of fetal programming and the effects of environmental exposures. Interventions aimed at improving nutrition and minimizing adverse environmental exposures may act synergistically to reverse the effects of these epigenetic marks and improve the outcome of our future generations.


Assuntos
Medicina Baseada em Evidências , Disparidades nos Níveis de Saúde , Serviços de Saúde Reprodutiva , Saúde Reprodutiva , Saúde da Mulher , Adolescente , Adulto , Envelhecimento , Pesquisa Biomédica , Epigênese Genética , Feminino , Custos de Cuidados de Saúde , Humanos , Pessoa de Meia-Idade , National Institutes of Health (U.S.) , Saúde Reprodutiva/economia , Saúde Reprodutiva/etnologia , Serviços de Saúde Reprodutiva/economia , Terminologia como Assunto , Estados Unidos , Saúde da Mulher/economia , Saúde da Mulher/etnologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...